High Fluence Light Emitting Diode-Red Light (LED-RL) in Human Skin

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
FibrosisScarringScarWoundsInjuriesKeloidCicatrixHypertrophic
Interventions
DEVICE

LED-RL Phototherapy

"The maximum recommended starting dose (MSRD) (160 J/cm2) will be administered to Group 1's LED-RL phototherapy randomized subjects and the LED-RL dose will be escalated in subsequent groups using the classical method for dose escalation as described by Spilker: starting with dose (X) increased by an equal amount (in this instance: X=160 J/cm2, 2X=320 J/cm2, 3X=480 J/cm2, 4X=640 J/cm2). Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity and is considered the upper limit of subject tolerance.~All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks."

DEVICE

Mock Therapy

"Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit and only generates warmth and does not emit LED-RL.~All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks."

Trial Locations (1)

95655

Sacramento VA Medical Center, Mather

All Listed Sponsors
collaborator

VA Northern California Health Care System

FED

collaborator

East Bay Institute for Research and Education

OTHER

lead

Jared Jagdeo, MD, MS

FED

NCT02630303 - High Fluence Light Emitting Diode-Red Light (LED-RL) in Human Skin | Biotech Hunter | Biotech Hunter